Design to come?

WP_Post Object
(
    [ID] => 2404
    [post_author] => 3
    [post_date] => 2024-11-18 16:20:39
    [post_date_gmt] => 2024-11-18 21:20:39
    [post_content] => 
    [post_title] => Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
    [post_excerpt] => 
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => intensity-therapeutics-presents-int230-6-phase-1-2-data-in-sarcoma-and-an-overview-of-its-ongoing-global-randomized-phase-3-sarcoma-trial-invincible-3-study-in-a-late-breaking-session-at-the-202
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2024-11-20 16:21:11
    [post_modified_gmt] => 2024-11-20 21:21:11
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => https://vcapital.com/?post_type=news&p=2404
    [menu_order] => 0
    [post_type] => news
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
)